ERBB2 and breast carcinoma: Similarly, the CAIRO2 study [61] on the hetero-combination of bevacizumab/cetuximab with oxaliplatin and capecitabine, the PACCE study [26] on bevacizumab/panitumumab combined with oxaliplatin and irinotecan in metastatic colorectal cancer, and the AVEREL [27] study on trastuzumab and bevacizumab in HER2-amplified breast cancer also were unsuccessful.